Glenmark Pharma Board Meeting on Nov 5 to Approve Unaudited Financial Results

Glenmark Pharmaceuticals Ltd has announced that its Board of Directors will convene on November 5, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. The results will be both standalone and consolidated. The company will submit the results to the stock exchanges and host them on its website on the same day. Concurrently, the trading window for designated persons will remain closed until November 7, 2026, reopening on November 8, 2026.